{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-001950","form_type":"8-K","ticker":"HEPA","cik":"0001583771","company_name":"Hepion Pharmaceuticals, Inc.","filed_at":"2022-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.201567+00:00","generated_at":"2026-06-27T20:13:40.395223+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Hepion's lead NASH drug gets USAN name 'rencofilstat'","bullets":["USAN Council adopted 'rencofilstat' as nonproprietary name for CRV431, Hepion's lead NASH/liver disease drug.","The name will be used in future publications, conferences, and clinical development steps.","Hepion is a clinical-stage biopharma focusing on AI-driven therapies for NASH and other liver diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-001950","json":"https://secwatch.observer/filing/0001104659-22-001950.json","markdown":"https://secwatch.observer/filing/0001104659-22-001950.md","text":"https://secwatch.observer/filing/0001104659-22-001950.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583771/000110465922001950/0001104659-22-001950-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583771/000110465922001950/tm221986d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T20:13:40.395223+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}